Healthcare sector | Medical Instruments & Supplies industry
| Price | $1.15 |
|---|---|
| Shares Outstanding | 9.68M |
| All-Time Low | $1.06 |
| 52-Week Low | $1.06 |
| Net Cash / Share | $0 |
|---|---|
| Net Current Assets / Share | $2.02 |
| Net Tangible Assets / Share | $4.56 |
| Shares Outstanding Ave Change (Annual) | 56.93% |
| Shares Δ YoY | 144.63% |
| Avg CA Burn (Annual %) | -41.67% (as of 2-20-2026) |
| Avg CA Burn (Quarterly %) | 1.79% (as of 2-20-2026) |
| Max Earning Power / Share | $-5.64 |
|---|---|
| Adjusted Earning Power |
$-8.37
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
22.59%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 0 (as of 2-20-2026) |
| Avg EBITDA (5Q) | 0 (as of 2-20-2026) |
| Avg Net Income (5Y) | -137.4M (as of 2-20-2026) |
| Avg Net Income (5Q) | -16.6M (as of 2-20-2026) |
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 2-20-2026 |
| Consecutive Years Paid | No | 2-20-2026 |
| Pays Dividend | No | 2-20-2026 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | No | 2-20-2026 |
| Net Income Positive | No | 2-20-2026 |
| Current Dividend Streak | No | 2-20-2026 |
Pick a metric to view its history table and chart.
Formula: Tangible Book Value / shares from balance statements. Includes 5 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-09-30 | Quarterly | $4.53 | 44.1M ($44,116,000) | 9.7M (9,730,400) |
| 2025-06-30 | Quarterly | $9.81 | 38.4M ($38,351,000) | 3.9M (3,909,400) |
| 2025-03-31 | Quarterly | $12.84 | 39.8M ($39,825,000) | 3.1M (3,101,400) |
| 2024-12-31 | Quarterly | $13.76 | 25.7M ($25,672,000) | 1.9M (1,865,400) |
| 2024-12-31 | Annual | $13.76 | 25.7M ($25,672,000) | 1.9M (1,865,400) |
| 2024-09-30 | Quarterly | $25.72 | 37.9M ($37,925,000) | 1.5M (1,474,466) |
| 2023-12-31 | Annual | $81.55 | 62.2M ($62,185,000) | 762.5K (762,533) |
| 2022-12-31 | Annual | $264.42 | 131M ($130,968,000) | 495.3K (495,304) |
| 2021-12-31 | Annual | $526.48 | 254.1M ($254,116,000) | 482.7K (482,670) |
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2024-12-31 | 30.8M ($30,776,000) |
| 2023-12-31 | 36.1M ($36,116,000) |
| 2022-12-31 | 27.8M ($27,802,000) |
| 2021-12-31 | 18M ($17,981,000) |
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| No dividend payment history available yet | |
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2025-09-25 | 9,680,265 | +4,925,000 |
| 2025-09-22 | 4,755,265 | +74,265 |
| 2025-08-19 | 4,681,000 | +1,317,000 |
Latest short-interest change: 1,166,447 shares (11.47% of float) | Days to cover: 5.29
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-03-12 | 1,166,447 shares | -32,064 | -2.68% |
| 2026-02-27 | 1,198,511 shares | +62,323 | +5.49% |
| 2026-02-11 | 1,136,188 shares | +82,106 | +7.79% |
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| No interesting volume events | ||||
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.